Immune-based, targeted therapy for allergic diseases

JAMA

Volumn 286, Issue 23, 2001, Pages 3005-3006

  Plaut, M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; MONOCLONAL ANTIBODY; OMALIZUMAB; UNCLASSIFIED DRUG;

ALLERGIC DISEASE; ALLERGIC RHINITIS; EDITORIAL; HUMAN; PATHOGENESIS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0035915308     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.286.23.3005     Document Type: Editorial

References (27)

1. Allergic and non-allergic rhinitis
2. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjuncitivitis, and atopic eczema: ISAAC
3. Asthma and allergic rhinitis among Finnish adolescents in 1977-1991
4. Pollen survey of the United States
5. The prevalence of allergic skin test reactivity to eight common aeroallergens in the US population
6. Genetics of allergic disease
7. Unique mechanistic features of allergic rhinitis
8. Allergic rhinitis: Definition, epidemiology, pathophysiology, detection and diagnosis
9. Allergic rhinitis
10. Quality of life and rhinitic symptoms
11. Complications of allergic rhinitis
12. Effect of omalizumab on symptoms of seasonal allergic rhinitis: A randomized controlled trial
13. Immunotherapy approach to allergic disease
14. Down-regulation of Fc (epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody
15. Treatment of allergic asthma with monoclonal anti-IgE antibody
16. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab)
17. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
18. Considerations in the evaluation of surrogate endpoints in clinical trials
19. Preventive aspects of immunotherapy: Prevention for children at risk of developing asthma
20. The value of hyposensitization therapy for bronchial asthma in children: A 14-year study
21. DNA-based immunotherapeutics for the treatment of allergic disease
22. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma
23. Initial immunotherapy trial to explore the safety, tolerability and immunogenicity of subcutaneous injections of an Amb a 1 immunostimulatory oligonucleotide conjugate (AIC) in ragweed allergic adults
24. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma
25. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response